Advantages of pyridostigmine bromide (mestinon) and edrophonium chloride (tensilon) in the treatment of transitory myasthenia gravis in the neonatal period.
D002648:Child; D003472:Curare / Q000037:antagonists & inhibitors*; D004491:Edrophonium; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases; D009157:Myasthenia Gravis; D010277:Parasympathomimetics / Q000627:therapeutic use*; D011729:Pyridostigmine Bromide
D010277:Parasympathomimetics; D004491:Edrophonium; D003472:Curare; D011729:Pyridostigmine Bromide
CURARE/antagonists; INFANT, NEWBORN/diseases; MYASTHENIA GRAVIS/in infant and child; PARASYMPATHOMIMETICS/therapeutic use